These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30349812)

  • 1. Can routine outpatient follow-up of patients with bladder cancer be improved? A multicenter prospective observational assessment of blue light flexible cystoscopy and fulguration.
    Zare R; Grabe M; Hermann GG; Malmström PU
    Res Rep Urol; 2018; 10():151-157. PubMed ID: 30349812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
    BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.
    Smith AB; Daneshmand S; Patel S; Pohar K; Trabulsi E; Woods M; Downs T; Huang W; Taylor J; Jones J; O'Donnell M; Bivalacqua T; DeCastro J; Steinberg G; Kamat A; Resnick M; Konety B; Schoenberg M; Jones JS; Lotan Y;
    BJU Int; 2019 Jan; 123(1):35-41. PubMed ID: 29979488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.
    Daneshmand S; Patel S; Lotan Y; Pohar K; Trabulsi E; Woods M; Downs T; Huang W; Jones J; O'Donnell M; Bivalacqua T; DeCastro J; Steinberg G; Kamat A; Resnick M; Konety B; Schoenberg M; Jones JS;
    J Urol; 2018 May; 199(5):1158-1165. PubMed ID: 29203268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem.
    Andersson M; Berger M; Zieger K; Malmström PU; Bläckberg M
    Scand J Urol; 2021 Aug; 55(4):263-267. PubMed ID: 34037496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
    Lotan Y; Bivalacqua TJ; Downs T; Huang W; Jones J; Kamat AM; Konety B; Malmström PU; McKiernan J; O'Donnell M; Patel S; Pohar K; Resnick M; Sankin A; Smith A; Steinberg G; Trabulsi E; Woods M; Daneshmand S
    Nat Rev Urol; 2019 Jun; 16(6):377-386. PubMed ID: 31019310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.
    Clinton TN; Lotan Y
    Future Oncol; 2018 Nov; 14(27):2805-2810. PubMed ID: 29925279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
    Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
    J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
    Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
    BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies.
    Hermann GG; Mogensen K; Toft BG; Glenthøj A; Pedersen HM
    Scand J Urol Nephrol; 2012 Feb; 46(1):31-6. PubMed ID: 22150596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
    World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer.
    Lee JS; Lee SY; Kim WJ; Seo SI; Jeon SS; Lee HM; Choi HY; Jeong BC
    Korean J Urol; 2012 Dec; 53(12):821-5. PubMed ID: 23301124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.